Table 3

Patient outcomes at baseline and follow-up

BaselineFour-month follow-upSix-month follow-up
Intervention
mean (SD), N
Control
mean (SD), N
Intervention
mean (SD), N
Control,
mean (SD), N
Intervention
mean (SD), N
Control
mean (SD,) N
Mean between-group difference* (95% CI)
Primary outcome
 MLHFQ, Overall38.2 (27.6), 2536.0 (26.5), 2535.5 (28.3), 2237.8 (27.9), 2329.2 (25.8), 2238.7 (30.1), 23−11.5 (−22.8 to 0.3)
 MLHFQ, Physical21.6 (13.4), 2519.8 (12.4), 2519.4 (13.5), 2220.7 (12.8), 2316.2 (12.3), 2120.3 (13.6), 23−4.7 (−10.1 to 0.8)
 MLHFQ, Emotional7.8 (9.1), 257.8 (8.4), 258.0 (8.5), 229.1 (8.6), 236.8 (8.1), 219.0 (8.5), 23−2.7 (−6.0 to 0.6)
Secondary outcomes
 HADS, Anxiety5.6 (4.8), 256.1 (4.9), 255.7 (4.8), 226.4 (5.4), 235.5 (5.1), 216.0 (5.1), 23−0.2 (−2.6 to 2.1)
 HADS, Depression6.2 (4.2), 255.6 (4.1), 255.6 (4.4), 226.6 (4.5), 235.4 (4.3), 216.9 (5.2), 23−1.5 (−3.4 to 0.3)
 Heart-QoL, Global1.4 (0.8), 251.6 (0.9), 251.5 (1.0), 221.4 (1.0), 231.8 (0.8), 211.4 (1.1), 230.5 (0.0 to 0.9)
 Heart-QoL, Physical1.2 (0.8), 251.4 (1.0), 251.3 (1.0), 221.3 (1.0), 231.6 (0.8), 211.3 (1.1), 230.5 (0.0 to 1.0)
 Heart-QoL, Emotional2.0 (1.0), 252.0 (1.0), 252.0 (1.0), 221.9 (1.0), 232.2 (1.0), 211.8 (1.1), 230.3 (−0.1 to 0.8)
 EQ-5D-3L, Index Score0.57 (0.29), 250.58 (0.31), 240.60 (0.28), 220.52 (0.34), 230.65 (0.31), 210.55 (0.29), 230.11 (−0.04 to 0.26)
 SCHFI, Maintenance51.9 (13.9), 2545.3 (16.5), 2568.9 (14.9), 2249.6 (14.4), 2364.2 (12.8), 2148.9 (14.3), 239.9 (2.5 to 17.3)
 SCHFI, Management37.6 (20.7), 2337.8 (18.4), 1848.9 (26.5), 1932.6 (19.2), 1745.0 (2.7), 1437.6 (23.5) 158.0 (−8.9 to 25.0)
 SCHFI, Confidence60.4 (25.5), 2556.9 (23.0), 2565.2 (18.7), 2249.5 (24.9), 2362.1 (20.0), 2153.4 (26.1), 236.6 (−6.7 to 19.9)
 ISWT (metres)183.6 (174.2), 25157.6 (117.8), 23218.9 (185.5), 18178.2 (115.0), 17224.7 (161.4), 17183.8 (98.1), 16−2.1 (−39.4 to 35.2)
 Accelerometry, number of days/week with at least 10 minutes/day activity>100 mg5.8 (2.3), 255.9 (2.0), 255.6 (2.4), 215.7 (1.9), 214.9 (2.7), 196.0 (2.1), 20−0.4 (−1.3 to 0.5)
 Accelerometry, average time/day at ≤20 mg (mins)1126 (98), 251090 (112), 251115 (110), 211103 (124), 211136 (101), 191098 (114), 20−10 (−49 to 28)
 Accelerometry, average time/day at 21 mg to 40 mg (mins)128 (33), 25152 (39), 25140 (38), 21143 (36), 21134 (37), 19148 (41), 2012 (−4 to 29)
 Accelerometry, average time/day at 41 mg to 60 mg (mins)77 (27), 2587 (29), 2579 (29), 2184 (33), 2175 (25), 1985 (27), 201 (−10 to 12)
 Accelerometry, average time/day at 61 mg to 80 mg (mins)45 (20), 2547 (20), 2545 (23), 2145 (21), 2140 (20), 1945 (19), 20−1 (−9 to 6)
 Accelerometry, average time/day at 81 mg to 100 mg (mins)25 (14), 2525 (15), 2525 (15), 2125 (17), 2122 (15), 1925 (15), 20−1 (−6 to 4)
 Accelerometry, average time/day at >100 mg (mins)39 (30), 2540 (48), 2536 (31), 2139 (52), 2132 (30), 1939 (48), 20−2 (−9 to 5)
  • *Mean between-group differences (intervention minus control) adjusted for baseline values.

  • HADS, Hospital Anxiety and Depression Scale; Heart-Qol, heart-related quality of life; ISWT, incremental shuttle walking test; MLHFQ, Minnesota Living with Heart Failure Questionnaire; SCHFI, Self-care of Heart Failure Index.